Skip to main content

Belsomra Disease Interactions

There are 6 disease interactions with Belsomra (suvorexant).

Major

Anxiolytics/sedatives/hypnotics (applies to Belsomra) depression

Major Potential Hazard, Moderate plausibility.

A variety of abnormal thinking and behavior changes have been reported to occur in association with the use of most anxiolytics, sedatives and hypnotics. Some of these changes include decreased inhibition, aggressiveness, agitation, and hallucinations. These drugs can cause or exacerbate mental depression and cause suicidal behavior and ideation. Therapy with these drugs should be administered cautiously in patients with a history of depression or other psychiatric disorders. Patients should be monitored for any changes in mood or behavior. It may be prudent to refrain from dispensing large quantities of medication to these patients.

References

  1. (2002) "Product Information. Buspar (buspirone)." Bristol-Myers Squibb
  2. (2001) "Product Information. Ambien (zolpidem)." sanofi-aventis
  3. (2001) "Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical
  4. (2001) "Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc
  5. (2001) "Product Information. Equanil (meprobamate)." Wallace Laboratories
  6. (2001) "Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories
  7. (2001) "Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical
  8. (2002) "Product Information. Xyrem (sodium oxybate)." Orphan Medical
  9. (2004) "Product Information. Lunesta (eszopiclone)." Sepracor Inc
  10. (2005) "Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America
  11. (2010) "Product Information. Silenor (doxepin)." Somaxon Pharmaceuticals
  12. (2013) "Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group
  13. (2014) "Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc
  14. (2014) "Product Information. Belsomra (suvorexant)." Merck & Co., Inc
View all 14 references
Major

Anxiolytics/sedatives/hypnotics (applies to Belsomra) severe renal impairment

Major Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

Some anxiolytic, sedative and hypnotic drugs have not been studied in patients with severe renal impairment and should not be used on these patients.

References

  1. (2002) "Product Information. Buspar (buspirone)." Bristol-Myers Squibb
  2. (2001) "Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories
  3. (2005) "Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America
  4. (2014) "Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc
  5. (2014) "Product Information. Belsomra (suvorexant)." Merck & Co., Inc
View all 5 references
Major

Suvorexant (applies to Belsomra) impaired respiratory function

Major Potential Hazard, Moderate plausibility. Applicable conditions: Pulmonary Impairment

Suvorexant has respiratory depressant effects and should be used with caution in patients with compromised respiratory function. Suvorexant has not been studied in patients with severe sleep apnea and severe COPD and should not be used in these patients.

References

  1. (2014) "Product Information. Belsomra (suvorexant)." Merck & Co., Inc
Major

Suvorexant (applies to Belsomra) narcolepsy

Major Potential Hazard, Moderate plausibility.

The use of suvorexant is contraindicated in patient with narcolepsy.

References

  1. (2014) "Product Information. Belsomra (suvorexant)." Merck & Co., Inc
Moderate

Anxiolytics/sedatives/hypnotics (applies to Belsomra) glaucoma

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Glaucoma/Intraocular Hypertension, Urinary Retention

Some hypnotic drugs can have an anticholinergic effect and should be used with caution in patients with glaucoma, and trouble urinating due to retention or enlarged prostate.

References

  1. (2002) "Product Information. Benadryl (diphenhydramine)." Parke-Davis
  2. (2013) "Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group
Moderate

Anxiolytics/sedatives/hypnotics (applies to Belsomra) liver disease

Moderate Potential Hazard, Moderate plausibility.

In general, anxiolytics, sedatives and hypnotics are extensively metabolized by the liver. Their plasma clearance may be decreased and their half-life prolonged in patients with impaired hepatic function. Therapy with these drugs should be administered cautiously in patients with liver disease (some are not recommended in severe liver impairment), and the dosage should be adjusted accordingly. Laboratory testing is recommended prior and during treatment.

References

  1. (2002) "Product Information. Buspar (buspirone)." Bristol-Myers Squibb
  2. (2001) "Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical
  3. (2001) "Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc
  4. (2001) "Product Information. Equanil (meprobamate)." Wallace Laboratories
  5. (2001) "Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories
  6. (2001) "Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical
  7. (2002) "Product Information. Xyrem (sodium oxybate)." Orphan Medical
  8. (2004) "Product Information. Lunesta (eszopiclone)." Sepracor Inc
  9. (2005) "Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America
  10. (2010) "Product Information. Silenor (doxepin)." Somaxon Pharmaceuticals
  11. (2011) "Product Information. Intermezzo (zolpidem)." Purdue Pharma LP
  12. (2014) "Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc
  13. (2014) "Product Information. Belsomra (suvorexant)." Merck & Co., Inc
View all 13 references

Belsomra drug interactions

There are 475 drug interactions with Belsomra (suvorexant).

Belsomra alcohol/food interactions

There is 1 alcohol/food interaction with Belsomra (suvorexant).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer